Understand the source comparison
DSIP Results After 2 Weeks: Research Peptide Comparison
DSIP (Delta Sleep-Inducing Peptide) GABA-A modulation, HPA axis suppression, delta-wave sleep enhancement Reduced sleep onset latency (10–15 min), 8–12% cortisol reduction, improved HRV 0.5–2mcg/kg nightly, subcutaneous Sleep architecture improves within 7–10
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP (Delta Sleep-Inducing Peptide)
- GABA-A modulation, HPA axis suppression, delta-wave sleep enhancement
- Reduced sleep onset latency (10–15 min), 8–12% cortisol reduction, improved HRV
- 0.5–2mcg/kg nightly, subcutaneous
- Sleep architecture improves within 7–10 days; metabolic changes require 4+ weeks
- MK 677 (Ibutamoren)
- Ghrelin receptor agonist, stimulates pulsatile GH and IGF-1 release
- Increased appetite within 48–72 hours, mild water retention, 15–25% GH elevation by day 14
- 12.5–25mg orally once daily
- Faster GH response than DSIP but hunger increase complicates fat loss
- CJC-1295 (DAC)
- GHRH analog, extends growth hormone pulse amplitude and duration
- Minimal subjective effects at 2 weeks; GH levels rise 20–30% but recomposition lag time similar to DSIP
- 1–2mg weekly, subcutaneous
- Works synergistically with DSIP; neither produces rapid visible results alone
- Cerebrolysin
- Neurotrophic peptide mixture, BDNF upregulation, neuroprotection
- Cognitive clarity and focus improvements within 5–7 days; no direct metabolic or sleep effects
- 5–10ml IM 2–3x weekly for 10–20 days
- Cognitive enhancement is faster and more pronounced than DSIP's sleep benefits
- BPC-157
- Promotes angiogenesis, enhances VEGF signaling, accelerates tissue repair
- Reduced joint or soft tissue discomfort within 7–10 days; sleep quality improvements secondary to pain reduction
- 250–500mcg daily, subcutaneous or oral
- Pain relief is noticeable quickly; DSIP's sleep mechanism is unrelated and complementary